A Phase 3, Randomized, Efficacy And Safety Study Of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, And Placebo Plus Leuprolide In Men With High-risk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy
Phase of Trial: Phase III
Latest Information Update: 24 Nov 2017
At a glance
- Drugs Enzalutamide (Primary) ; Leuprorelin
- Indications Adenocarcinoma; Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms EMBARK
- Sponsors Medivation; Pfizer
- 27 Oct 2017 Planned End Date changed from 13 Dec 2024 to 13 Jun 2024.
- 27 Oct 2017 Planned primary completion date changed from 30 Sep 2021 to 31 Mar 2021.
- 18 Aug 2017 Planned End Date changed from 9 Nov 2024 to 1 Dec 2024.